These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1445528)

  • 1. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study.
    Weintraub M
    Clin Pharmacol Ther; 1992 May; 51(5):581-5. PubMed ID: 1445528
    [No Abstract]   [Full Text] [Related]  

  • 2. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenfluramine and phentermine.
    Howlin D
    Ann Intern Med; 2001 Nov; 135(9):840-1. PubMed ID: 11694113
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
    Weintraub M; Sundaresan PR; Schuster B; Moscucci M; Stein EC
    Clin Pharmacol Ther; 1992 May; 51(5):602-7. PubMed ID: 1587074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. After fen-phen.
    Cowley G; Springen K
    Newsweek; 1997 Sep; 130(13):46-8. PubMed ID: 10173270
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
    Weintraub M; Sundaresan PR; Schuster B; Ginsberg G; Madan M; Balder A; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):595-601. PubMed ID: 1587073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term drug treatment of obesity in a private practice setting.
    Atkinson RL; Blank RC; Schumacher D; Dhurandhar NV; Ritch DL
    Obes Res; 1997 Nov; 5(6):578-86. PubMed ID: 9449143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):615-8. PubMed ID: 1587076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fen-phen finale: a study of weight loss and valvular heart disease.
    Wadden TA; Berkowitz RI; Silvestry F; Vogt RA; St John Sutton MG; Stunkard AJ; Foster GD; Aber JL
    Obes Res; 1998 Jul; 6(4):278-84. PubMed ID: 9688104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological approaches to intervention.
    Guy-Grand B
    Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S22-4. PubMed ID: 9130037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
    Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
    Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
    Weintraub M; Sundaresan PR; Madan M; Schuster B; Balder A; Lasagna L; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):586-94. PubMed ID: 1587072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term weight control study. VI. Individual participant response patterns.
    Weintraub M; Sundaresan PR; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):619-33. PubMed ID: 1587077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss.
    Katz DA; Maloney MJ; Sutkamp JC; McConville BJ
    Int J Eat Disord; 1999 May; 25(4):469-74. PubMed ID: 10202659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of obesity with drugs.
    Hirsch J
    Am J Clin Nutr; 1998 Jan; 67(1):2-4. PubMed ID: 9440366
    [No Abstract]   [Full Text] [Related]  

  • 17. The fenfluramine/phentermine combination for weight loss.
    Garrett SD; Cupp MJ
    Nurse Pract; 1997 Aug; 22(8):166, 168, 170. PubMed ID: 9279853
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful appetite suppression therapy with fenfluramine and phentermine in the obese diabetic transplant patient.
    Khan M; Lum CT; Rao V
    Transplant Proc; 1995 Feb; 27(1):975-6. PubMed ID: 7879251
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet alpha-adrenergic receptors in obesity: alteration with weight loss.
    Sundaresan PR; Weintraub M; Hershey LA; Kroening BH; Hasday JD; Banerjee SP
    Clin Pharmacol Ther; 1983 Jun; 33(6):776-85. PubMed ID: 6303674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity.
    Rothman RB
    J Clin Psychiatry; 1996 Feb; 57(2):92-3. PubMed ID: 8591979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.